Clinical Trial

Heartburn, Gastroesophageal Reflux Disease

Study acronym: GERD
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2025 (before its estimated May 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation. GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life. This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-25; most recent amendment 2025-12-16.
Trial Details
NCT Number NCT07268820
Lead Sponsor Incheon St.Mary's Hospital
Conditions GERD
Enrollment 160 participants
Start Date 2025-07-07
Primary Completion 2026-05-29 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-23